Loading
MMAE is the tubulin-blocking payload in brentuximab, enfortumab, polatuzumab and tisotumab vedotin, four approved ADCs: it halts cell division and, being membrane permeable, leaks into neighbouring tumour cells. Nerve damage and low neutrophil counts are its signature side effects.
Monomethyl auristatin E is a synthetic analogue of dolastatin 10 that binds tubulin and halts mitosis. Released by cleavable linkers (typically valine-citrulline), it is membrane permeable, giving a strong bystander effect. It is a substrate for P-glycoprotein, which drives resistance. Peripheral neuropathy and neutropenia are class effects seen with brentuximab vedotin, enfortumab vedotin, polatuzumab vedotin and tisotumab vedotin.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Showing the molecule this term concerns: Enfortumab vedotin.
Shares Bystander effect (ADC), Tubulin inhibitor payloads, Payload (ADC), Mitosis & the spindle assembly checkpoint.
Shares Bystander effect (ADC), Tubulin inhibitor payloads, Payload (ADC), Mitosis & the spindle assembly checkpoint.
Shares Bystander effect (ADC), Tubulin inhibitor payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Bystander effect (ADC), Drug efflux pumps (ABC transporters), Drug efflux pumps (ABC transporters), Payload (ADC).
Shares Drug efflux pumps (ABC transporters), Drug efflux pumps (ABC transporters), Payload (ADC), Antibody-drug conjugate (ADC).
Shares Drug efflux pumps (ABC transporters), Payload (ADC), Antibody-drug conjugate (ADC).
Shares Payload (ADC), Enfortumab vedotin, Antibody-drug conjugate (ADC).
Shares Bystander effect (ADC), Payload (ADC), Antibody-drug conjugate (ADC).